@article{3bb495388a44444f8c129aedf06fc32c,
title = "Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma",
abstract = "Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.",
keywords = "autophagy, CGAS, immune checkpoint inhibitors, PARP inhibitors, VEGFA, venetoclax",
author = "Vanessa Klapp and Lorenzo Galluzzi",
note = "Funding Information: The L.G. lab is supported by a Breakthrough Level 2 grant from the US DoD BRCP (# BC180476P1 ), by the 2019 Laura Ziskin Prize in Translational Research (# ZP-6177 , PI: Formenti) from Stand Up to Cancer , by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society , by a startup grant from the Department of Radiation Oncology at Weill Cornell Medicine , by a Rapid Response Grant from the Functional Genomics Initiative , by industrial collaborations with Lytix Biopharma and Phosplatin , and by donations from Phosplatin, the Luke Heller TECPR2 Foundation , Sotio a.s., Onxeo, Ricerchiamo, and Noxopharm . Funding Information: The L.G. lab is supported by a Breakthrough Level 2 grant from the US DoD BRCP (#BC180476P1), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI: Formenti) from Stand Up to Cancer, by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society, by a startup grant from the Department of Radiation Oncology at Weill Cornell Medicine, by a Rapid Response Grant from the Functional Genomics Initiative, by industrial collaborations with Lytix Biopharma and Phosplatin, and by donations from Phosplatin, the Luke Heller TECPR2 Foundation, Sotio a.s. Onxeo, Ricerchiamo, and Noxopharm. L.G. holds research contracts with Lytix Biopharma and Phosplatin, and has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. V.C. has no conflicts to declare. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2022",
month = jan,
doi = "10.1016/j.trecan.2021.11.006",
language = "English",
volume = "8",
pages = "1--3",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "1",
}